Patents by Inventor Diana Cherbavaz

Diana Cherbavaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20220396842
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Application
    Filed: August 19, 2022
    Publication date: December 15, 2022
    Inventors: Steven SHAK, Frederick L. Baehner, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Gene expression profile algorithm and test for determining prognosis of prostate cancer
    Patent number: 11011252
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: May 18, 2021
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20200255911
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 13, 2020
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20190249260
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method for using gene expression to determine prognosis of prostate cancer
    Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20160097105
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 7, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer
    Publication number: 20140303002
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Application
    Filed: March 21, 2014
    Publication date: October 9, 2014
    Applicant: Genomic Health, Inc.
    Inventors: Steven Shak, Mark Lee, William F. Novotny, Tara Maddala, Michael R. Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • Gene expression profile algorithm and test for determining prognosis of prostate cancer
    Patent number: 8725426
    Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: May 13, 2014
    Assignee: Genomic Health, Inc.
    Inventors: Steve Shak, Mark Lee, William Novotny, Tara Maddala, Michael Crager, Diana Cherbavaz, Robert J. Pelham, Carl L. Millward, Dejan Knezevic
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20120028264
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 2, 2012
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker